At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 122 enrolled
Drug / intervention
SPARC1102 I +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
Sun Pharma Advanced Research Company Limited·interventional·Posted Mar 22, 2011·Updated Jun 24, 2016
In Brief
A Phase 2 clinical trial evaluating SPARC1102 I, SPARC1102 II, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 122 participants across 1 site.
Detailed Summary
The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartJun 2011
Primary CompletionAug 2011
Study CompletionSep 2011
TodayJul 2026
First PostedMar 22, 2011
Enrollment StartJun 1, 2011
Primary CompletionAug 1, 2011
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.3 years ago
Interventions
SPARC1102 Idrug
SPARC1102 I will be administered in both eyes
SPARC1102 IIdrug
SPARC1102 II will be administered in both eyes
SPARC1102 IIIdrug
SPARC1102 III will be administered in both eyes
Vehicledrug
Vehicle will be administered in both eyes